Quantcast

Monday, June 6, 2011

Top News From American Heart Association (AHA) 2010 scientific sessions

The American Heart Association (AHA) 2010 Scientific Sessions took place in Chicago, Illinois, November 13-17, 2010.
Key trials presented at the sessions include:
  • ADVANCE: New LVAD equivalent to HeartMate II, nonrandomized study shows
  • RAFT: CRT shows survival benefit for patients with class 2 and 3 HF who have low EF and wide QRS
  • EMPHASIS-HF: Eplerenone shows large benefits in milder heart failure
  • ASCEND HF: Nesiritide safe but of limited dyspnea benefit in acute HF
  • ROCKET AF: Rivaroxaban noninferior to warfarin, but superiority analyses at odds
  • CLOSURE I: No overall benefit, no reduction in stroke or TIA with PFO closure
  • GRAVITAS: No benefit of doubling dose in clopidogrel nonresponders
  • P-OM3: Omega-3 PUFA caps don't suppress paroxysmal AF in randomized trial
  • BASKET-PROVE: DES as safe as bare-metal stents in larger coronary arteries, with less TVR 
  • DEFINE: Large effects on LDL and HDL cholesterol with CETP inhibitor anacetrapib
  • SYMPLICITY HTN: Catheter-based renal denervation reduces BP in patients with resistant hypertension
  • ASCOT CRP: Analysis fuels debate over JUPITER-based CRP indication for statins
  • ACT: No benefit of N-acetylcysteine to reduce contrast-induced nephropathy

1 comment:

  1. A complete well-written post. I apprehend and admired the adjustment and acquire aswell bookmarked you. All the best for abutting endeavors.
    Estetik

    ReplyDelete

Add your comment

Free Books, powerpoint presentations, teaching tools and resources and drug information